Hard To Treat Diseases, Inc. (PN CE) (USOTC:HTDS)
Historical Stock Chart
5 Years : From Jun 2014 to Jun 2019
Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) -
The world's first clinical trial of human embryonic stem cell (hESC) - based therapy for the treatment of acute spinal cord injuries in man has been approved by FDA and will be performed by Geron Corporation and the University of California, Irvine. (Source http://stemcell.uci.edu/).
Professor Mirjana Stojiljkovic, principal scientist and medical advisor from Slavica BioChem (www.slavicabiochem.com), a subsidiary of Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS), http://www.htdsmedical.com said that this is a major breakthrough for the whole field of regenerative medicine, especially concerning the treatment of neurodegenerative diseases. As the Geron officials reported, they are now formally exploring the utility of hESC-Derived Oligodendrocyte Progenitor Cells (OPC) in other degenerative CNS disorders including Alzheimer's, multiple sclerosis (MS) and Canavan disease.
Multiple sclerosis, which is, along with the traumatic brain injury, in the focus of research of the Slavica BioChem scientific team, is a demyelinating disease affecting brain and spinal cord. Demyelination is the process of degeneration of myelin, the insulating sheath around the nerve fibers. Myelin is produced by oligodendrocytes. In MS treatment, oligodendrocytes need to be "replaced" in order to have new myelin produced. This is where the hESC-Derived Oligodendrocyte Progenitor Cells (OPC) come into play. Geron team in collaboration with the University of California has shown in animal models that OPC can improve functional locomotor behavior after grafting in the injury site seven days after injury.
Dr Sanja Pekovic, Chief Project Scientist and Chief Strategy Officer of HTDS adds that the research Slavica Biochem is performing on MS is along the lines with these general notions in MS treatment. Namely, Slavica Biochem is performing research on substances, which can be used as add-on therapy to the hESC-cell based therapy. These chemicals will be tested for their capability of promoting stem cell graft survival. Slavica Biochem team also plans on establishing collaboration on these topics with research teams from USA, especially after the Agreement on Scientific and Technological cooperation between the Republic of Serbia and the United States of America (USA) has been signed in April this year. See link for further details: www.nauka.gov.rs/eng/index.php?option=com_content&task=view&id=394&Itemid=55.
In view of the above and further to the company news release of July 29, 2010 HTDS management continues its diversification of Slavica Biochem and outright sale discussions with a USA based Bio Chem company. HTDS management is seeking ways and means to bolster its share values to its shareholders and generally increase value to HTDS.
About Mina Mar Group:
Mina Mar Group pioneered the "Go Public Free" program, the first firm to challenge the short sellers, stock bashers and repeal of the "Communication Decency Act". Visit www.minamargroup.com/ice to learn more.
Mina Mar Marketing Group, MMMG (www.minamargroup.net/) offers publicly traded companies full array of services such as Investor Relations and maintenance investor awareness.
To be included in company's email database for press releases, "Friday Tips", industry updates, and company activity that may or may not be news released, please subscribe for opt-in mailer at http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases, Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Investor Relations Department Inquiry, www.minamargroup.net
(IR), for (M&A) and Corporate Matters, www.minamargroup.com
Hard to Treat Diseases, Inc: firstname.lastname@example.org